Warning Letter Record: ABS Corporation (2026-07-23) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
The short version: The FDA Center for Veterinary Medicine issued a warning letter to ABS Corporation (7031 N 16th St, Omaha, Nebraska) on July 23, 2026, following an inspection conducted January 12-16, 2026 (CMS Case 732115), citing significant Current Good Manufacturing Practice (CGMP) violations under 21 CFR parts 210 and 211. The FDA documented that ABS Corporation released multiple animal drug product batches with out-of-specification test results without performing required corrective actions, including failing to execute mandatory adjustments specified in approved Master Production Records, averaging analytical results to mask individual failures, and manually altering specification limits without scientific justification or documentation. The agency stated these violations render the drug products adulterated under section 501(a)(2)(B) of the FD&C Act, and the company committed to revising procedures to prohibit result averaging, require documented scientific justification for retesting, and mandate Quality Assurance approval for all out-of-specification batch disposition decisions.
Argus analysis
# FDA Warning Letter Analysis: ABS Corporation
**Company and Violations**
ABS Corporation, a veterinary pharmaceutical manufacturer based in Omaha, Nebraska, received a Current Good Manufacturing Practice (CGMP) warning letter from the FDA's Center for Veterinary Medicine on July 23, 2026, following an inspection conducted January 12–16, 2026. The FDA determined that the company's manufacturing methods, facilities, and controls for finished pharmaceuticals did not conform to CGMP regulations, rendering its drug products adulterated under the Federal Food, Drug, and Cosmetic Act.
**Regulatory Citations**
The violations centered on two primary regulatory areas: 21 CFR 211.192 (batch investigation and release) and 21 CFR 211.84(a) and (d) (component testing and quality control). These sections require manufacturers to investigate out-of-specification (OOS) results with scientific justification before releasing batches and to test all incoming components for identity and specifications before use. ABS Corporation released multiple animal drug batches with confirmed OOS results without performing required corrective adjustments mandated by its approved Master Production Records, and used expired raw materials—including high-risk components—before receiving retest data or with failed retest results.
**Timeline and Industry Watch Points**
ABS Corporation submitted a response on January 30, 2026, which the FDA deemed inadequate for failing to address safety and disposition of distributed products. The warning letter explicitly requests a comprehensive independent assessment of deviation and OOS investigation systems, plus a detailed remediation plan with specific timelines. Compliance officers in animal pharmaceutical manufacturing should monitor whether ABS Corporation issues a revised response with retrospective product safety assessments, timelines for procedure revisions, and evidence of quality unit oversight strengthening. Regulatory observers typically watch for follow-up inspections within 12–24 months to verify implementation of corrective actions.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER ABS Corporation MARCS-CMS 732115 — July 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Drugs Recipient: Recipient Name Mr. David G. Wood Recipient Title President/CEO ABS Corporation 7031 N 16th St. Omaha , NE 68112 United States Issuing Office: Center for Veterinary Medicine United States July 23, 2026 CMS Case: 732115 WARNING LETTER Dear Mr. Wood: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, ABS Corporation, located at 7031 N 16th St. Omaha, Nebraska, from January 12th to 16th 2026. This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 351(a)(2)(B). Current Good Manufacturing Practice Violations We reviewed your January 30, 2026, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding this inspection. Our review of the evidence gathered during the inspection and your response revealed significant violations, including the following. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Your firm manufactures animal drugs for (b)(4) and (b)(4) use. Your firm released drug products with confirmed out of specification (OOS) results without performing corrective actions explicitly required by your approved Master Production Records (MPR). For example, during the manufacture of (b)(4) , your firm repeatedly failed to perform required (b)(4) adjustments and released batches with confirmed OOS (b)(4) results. For Lot (b)(4) , finished product testing yielded an OOS (b)(4) result of 4.03 (specification: (b)(4) ). During your corrective and preventative action (CAPA) investigation, internal retesting of three individual bottles produced (b)(4) results of 4.49, 4.51, and 4.40 — the third result of 4.40 also failed to meet the established specification. Rather than invalidating the OOS result through a scientifically justified investigation, your firm (b)(4) the three results ( (b)(4) ), (b)(4) to (b)(4) , and released the batch for distribution on July 21, 2025. Your investigation identified that the root cause was an in- process OOS result for (b)(4) and that the required corrective (b)(4) adjustment using (b)(4) , as specified in your approved MPR, had not been performed. Similarly, for Lot (b)(4) , your firm obtained an in-process (b)(4) res…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has ABS Corporation had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for ABS Corporation as of 2026-08-04. Argus ingests new FDA enforcement records daily.
- What FDA violations was ABS Corporation cited for?
- The FDA Warning Letter to ABS Corporation (issuing office: Center for Veterinary Medicine) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: ABS Corporation (2026-07-23) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-abs-corporation-2026-07-23-cgmp
"Warning Letter Record: ABS Corporation (2026-07-23) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-abs-corporation-2026-07-23-cgmp.
Argus HQ Research. "Warning Letter Record: ABS Corporation (2026-07-23) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed August 5, 2026. https://argushq.ai/fda/warning-letter/fda-wl-abs-corporation-2026-07-23-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_abs_corporation_2026_07_23_cgmp_2026,
title = {Warning Letter Record: ABS Corporation (2026-07-23) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-abs-corporation-2026-07-23-cgmp},
note = {Accessed: August 5, 2026}
}